Ionis Pharmaceuticals (MEX:IONS) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Ionis Pharmaceuticals Effective Interest Rate on Debt % Related Terms
Ionis Pharmaceuticals Effective Interest Rate on Debt % Historical Data
* Premium members only.
The historical data trend for Ionis Pharmaceuticals's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals Effective Interest Rate on Debt % Chart
MEX:IONS vs EXEL, BBIO, AXSM: Effective Interest Rate on Debt % Comparison
For the Biotechnology subindustry, Ionis Pharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals Effective Interest Rate on Debt % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's Effective Interest Rate on Debt % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data,
the Interest Expense data used here is four times the quarterly (Mar. 2026) interest expense data.
Effective Interest Rate on Debt % is displayed in the 30-year financial page.
What does a Effective Interest Rate on Debt % of 3.97% mean?
Ionis Pharmaceuticals (MEX:IONS) has a Effective Interest Rate on Debt % of 3.97% as of Mar. 2026. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Effective Interest Rate on Debt % too high?
Ionis Pharmaceuticals' current Effective Interest Rate on Debt % is 3.97%. Overall, Ionis Pharmaceuticals has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Effective Interest Rate on Debt % compare to EXEL and BBIO?
Ionis Pharmaceuticals' Effective Interest Rate on Debt % of 3.97% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Effective Interest Rate on Debt % is 3.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current Effective Interest Rate on Debt % of 3.97%. The stock's GF Value™ is MXN1,062.74, compared to a current price of MXN1,150.00 — trading 8.2% above its estimated fair value. The current Effective Interest Rate on Debt % is 3.97%. Ionis Pharmaceuticals' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Effective Interest Rate on Debt % is 3.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN1,150.00 is trading 8.2% above its estimated GF Value™ of MXN1,062.74.
Key valuation signals for MEX:IONS:
Effective Interest Rate on Debt %: 3.97%
GF Value™: MXN1,062.74 vs. price of MXN1,150.00 (8.2% above fair value)
No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
72GF Score
Get the complete analysis for MEX:IONS
Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:IONS has been successfully added to your 
